JSA advised Biocon Biologics Limited in the sale of its Indian branded formulations business to Eris Lifesciences Limited for an aggregate consideration of INR 1,242 Crore. As part of this deal, Biocon Biologics Limited also signed a 10-year supply agreement with Eris Lifesciences Limited.
Biocon Biologics Limited is a unique, fully integrated leading global biosimilars player with established capabilities in the development, manufacturing and commercialization of high-quality biosimilars. This collaboration is in-line with Biocon Biologics’ strategy to unlock value from its legacy business of branded formulations built over the past two decades and extends its existing partnership with Eris for Biocon’s Nephrology and Dermatology business announced in December 2023.
JSA assisted Biocon in navigating complex legal issues, including those under Indian pharmaceutical regulations, intellectual property laws and tax laws, each of which had material commercial implications for the transaction. The team helped the client balance various commercial considerations while structuring the deal and helped parties enter this long-term collaboration seamlessly.
Our transaction team comprised lead partner – Probir Roy Chowdhury, partner – Yajas Setlur, senior associate – Soumya Bhargava, associate – Moushami Nayak and Nikhil George.
Nikhil is a member of the technology, media and telecommunications (TMT) team at JSA. He has experience in regulatory advisory and transactions, predominantly in the technology sector.